Herpes simplex virus type 1 is one of the most widespread human infections on the planet, carried by roughly two-thirds of the global population under age 50. An estimated 3.7 billion people were living with HSV-1 infection as of 2016, a prevalence of about 67%.1PubMed Central. Herpes simplex virus: global infection prevalence and incidence estimates, 2016 Most people think of it as the virus behind cold sores, and that is its most familiar face. But HSV-1 has a far more complex biology than a recurring lip blister suggests, with implications ranging from genital infections to eye disease, brain inflammation, and even a possible link to Alzheimer’s disease.
How HSV-1 Gets Into Your Cells
HSV-1 infection starts when the virus lands on a cell surface and latches onto sugar molecules called heparan sulfate. That initial grip triggers a chain of interactions between viral proteins on the virus’s outer envelope and specific receptors on the host cell, ultimately allowing the virus’s core to slip inside.2PubMed Central. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry The main cellular doorway in skin cells is a protein called nectin-1. In mouse skin tissue, blocking nectin-1 dramatically reduced viral entry. A backup receptor called HVEM can partially fill in when nectin-1 is missing, which illustrates the virus’s flexibility: it has evolved multiple routes into tissue rather than depending on a single lock-and-key match.3PubMed Central. Entry mechanisms of herpes simplex virus 1 into murine epidermis: involvement of nectin-1 and herpesvirus entry mediator as cellular receptors
Once inside, HSV-1 hijacks the cell’s internal transport system to move its genetic material to the cell nucleus, where it begins replicating. The virus rides along microtubules and actin filaments, the same scaffolding the cell uses for its own internal shipping, repurposing those structures to shuttle viral components where they need to go.4PubMed Central. Infection and Transport of Herpes Simplex Virus Type 1 in Neurons: Role of the Cytoskeleton This co-opting of the host’s own machinery is a recurring theme in HSV-1’s survival strategy.
How the Virus Hides for Life
After the initial infection clears from the skin or mucous membranes, HSV-1 travels along nerve fibers to sensory nerve cell clusters called ganglia, most commonly the trigeminal ganglion near the base of the skull. There it enters a dormant state known as latency. The viral DNA remains inside the neuron’s nucleus but stops making most of its proteins. This is not passive hiding; the virus actively silences its own replication genes.
A key player in this silencing is the latency-associated transcript, or LAT, a stretch of RNA that HSV-1 produces during dormancy. LAT promotes the assembly of tightly packed chromatin structures on the virus’s gene-activation switches. In experiments comparing viruses with and without functional LAT, the LAT-positive virus accumulated more of the chemical marks associated with gene silencing on its own replication-related genes.5PubMed Central. Herpesviral latency-associated transcript gene promotes assembly of heterochromatin on viral lytic-gene promoters in latent infection Further work showed that LAT drives the formation of a specific type of silent chromatin that cells normally use to shut down their own unneeded genes, suggesting the virus has learned to borrow a host cell trick for its own purposes.6PubMed Central. Transcription of the herpes simplex virus latency-associated transcript promotes the formation of facultative heterochromatin on lytic promoters
LAT also directly affects how often the virus wakes up. Research in mice found that LAT represses gene activity in small populations of neurons within the nerve ganglion, and this repression directly reduces the frequency of reactivation.7PLOS Pathogens. The HSV-1 Latency-Associated Transcript Functions to Repress Latent Phase Lytic Gene Expression and Suppress Virus Reactivation from Latently Infected Neurons Paradoxically, the virus benefits from keeping itself quiet. Frequent reactivation would provoke a stronger immune attack and risk killing the neurons that serve as its permanent reservoir. So LAT helps the virus thread the needle between total silence and occasional reactivation.
Your immune system plays an active role in policing this truce. CD8+ T cells cluster around latently infected neurons and appear to help keep the virus suppressed.8PubMed. Immune control of HSV-1 latency The balance between immune surveillance and viral silencing determines whether the virus stays dormant or flares up.
What Triggers Reactivation
When that balance tips, HSV-1 breaks out of latency. The virus begins making its replication proteins again, produces new copies of itself, and sends them back down the nerve fibers to the skin or mucous membranes. This is what produces a cold sore or other recurrence. Triggers include physical and emotional stress, fever, sun exposure, illness, and immune suppression. Different stimuli appear to activate distinct cellular pathways that converge on the same outcome: reactivation of viral gene expression and production of infectious virus.9PubMed Central. Strength in diversity: Understanding the pathways to herpes simplex virus reactivation
The frequency and severity of recurrences vary widely. Some people get cold sores several times a year; many carriers never have a recognizable outbreak at all. This variability is partly genetic, partly immunological, and partly a matter of where in the nerve ganglion the virus has set up camp. There is no reliable way to predict a given person’s recurrence pattern from their initial infection.
Oral Herpes and Its Symptoms
The classic first encounter with HSV-1 is primary herpetic gingivostomatitis, an illness that mainly hits children and young adults. It typically shows up as clusters of tiny blisters inside the mouth that quickly burst into painful, shallow ulcers covered by yellowish-gray membranes. Fever, swollen lymph nodes under the jaw, bad breath, and refusal to eat or drink are common accompanying signs.10PubMed. Herpes simplex virus infection, with particular reference to the progression and complications of primary herpetic gingivostomatitis The illness is self-limiting in most cases but can be severe enough to require hospital admission in a minority, roughly 13 to 30% of symptomatic primary infections.11PubMed Central. Supportive care and antiviral treatments in primary herpetic gingivostomatitis: a systematic review
The important caveat is that the vast majority of primary HSV-1 infections cause no noticeable symptoms at all. Most people acquire the virus in childhood without knowing it, making gingivostomatitis the visible tip of an enormous iceberg. Recurrent oral herpes — the familiar cold sore on or near the lip — is generally milder, typically a small cluster of blisters that crusts over and heals within a week or two. These recurrences can be triggered by stress, illness, immune compromise, or other factors and tend to recur throughout life.12Reviews in Medical Microbiology. Oral infections of herpes simplex virus: symptoms, diagnosis, treatment and pathophysiology in periodontal disease
The Rise of Genital HSV-1
One of the more significant epidemiological shifts in recent decades is the growing role of HSV-1 as a cause of genital herpes. In a study of college students in the United States, the proportion of new genital herpes cases caused by HSV-1 rose from 31% in 1993 to 78% in 2001.13Sexually Transmitted Diseases. Increasing Proportion of Herpes Simplex Virus Type 1 as a Cause of Genital Herpes Infection in College Students This trend has continued. In several high-income regions, including North America and Western Europe, HSV-1 has become the leading cause of first-episode genital herpes, particularly among adolescents and young adults.14PubMed. From HSV-2 to HSV-1: A change in the epidemiology of genital herpes
The likely explanation is generational. As childhood oral HSV-1 infection has become less common in wealthier countries (due to improved hygiene and smaller family sizes), more young adults reach sexual debut without prior HSV-1 antibodies. Without that preexisting immunity, they are susceptible to acquiring HSV-1 genitally through oral sex. Global estimates suggest about 376 million people aged 15–49 were living with genital HSV-1 infections as of 2020.15Sexually Transmitted Infections. Estimated global and regional incidence and prevalence of herpes simplex virus infections and genital ulcer disease in 2020: mathematical modelling analyses Earlier estimates from 2012 put the figure much lower, around 140 million, though differences in methodology make direct comparison difficult.16PLOS ONE. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012
One practical distinction: genital HSV-1 tends to recur less often than genital HSV-2. Many people with genital HSV-1 have one or two outbreaks and then very few thereafter. That does not mean it cannot be transmitted, though, because asymptomatic shedding still occurs.
Asymptomatic Shedding
You do not need to have a visible sore to pass HSV-1 to someone else. The virus periodically reactivates and reaches the skin surface without causing noticeable symptoms, a process called asymptomatic shedding. Most transmissions to sexual partners and newborns happen during these silent episodes.17PubMed. Transmission and viral shedding In people with genital HSV-1, a study tracking viral shedding for a year after the first episode found that most genital shedding was asymptomatic, while oral shedding and visible lesions were uncommon.18PubMed Central. Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection
This is a source of frustration and confusion for many people. The idea that you can transmit a virus without knowing it is active undercuts the common assumption that avoiding contact during outbreaks is sufficient to prevent spread. It isn’t, though outbreak periods carry the highest viral load. Daily antiviral therapy reduces shedding frequency, which is one reason clinicians sometimes recommend it for people in serodiscordant partnerships (where one partner carries the virus and the other does not).
Complications Beyond the Skin
For most people, HSV-1 means occasional cold sores at worst. But the virus is capable of causing serious disease in certain contexts.
Eye Infections
HSV-1 keratitis, an infection of the cornea, is a leading cause of infectious blindness worldwide. The virus reaches the eye either during a primary infection or through reactivation from the trigeminal ganglion, which also supplies nerve fibers to the cornea. Once in the cornea, HSV-1 triggers a chronic inflammatory response that can lead to scarring, thinning, growth of new blood vessels into normally clear tissue, and progressive clouding of vision.19PubMed Central. Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea Recurrent episodes are the major concern: each flare risks additional damage and scarring.20PubMed Central. Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation Prompt antiviral treatment can control the infection, but some patients eventually need corneal transplantation.
Herpes Simplex Encephalitis
The most feared complication is herpes simplex encephalitis, or HSE, a rare but devastating brain infection. HSE preferentially strikes the temporal and frontal lobes of the brain, causing swelling, bleeding, and tissue death.21PubMed. Mechanisms of Blood-Brain Barrier Disruption in Herpes Simplex Encephalitis The infection also disrupts the blood-brain barrier, allowing a flood of immune cells and inflammatory signals into the brain that contribute to further damage. Even with antiviral treatment, survivors often face long-term consequences including memory loss, personality changes, and seizures. HSE is uncommon, but because HSV-1 is so widespread, it remains the most frequent cause of sporadic viral encephalitis in many countries.
Treatment and Antiviral Resistance
The standard treatment for HSV-1 infections is a class of drugs that interfere with viral DNA replication. Acyclovir (and its better-absorbed oral form, valacyclovir) has been the backbone of herpes treatment for decades. These drugs work by mimicking a building block of DNA: the virus’s own enzyme activates the drug, which then jams the replication machinery. This targeted activation is why they are relatively well tolerated and why they affect the virus far more than healthy cells.
Resistance, though still uncommon in people with healthy immune systems, is a growing concern in immunocompromised patients. A comprehensive review identified hundreds of drug-resistance mutations across the HSV-1 and HSV-2 genomes. When researchers compared lab-based resistance testing with clinical outcomes, the two agreed about 90% of the time. All the disagreements involved viruses that looked susceptible in the lab but behaved as resistant in actual patients, a discrepancy that suggests real-world resistance may be slightly more common than lab tests indicate.22Clinical Microbiology and Infection. Herpes simplex virus and drug resistance—comprehensive update on resistance mutations and implications for clinical management: a narrative review
Newer Antivirals on the Horizon
The limitations of acyclovir have pushed researchers toward a different viral target: the helicase-primase complex, a molecular machine HSV uses to unwind and copy its DNA. Two drugs that block this complex, pritelivir and amenamevir, have reached clinical use or advanced trials. Amenamevir is already approved in Japan for shingles (caused by a related herpesvirus), while pritelivir has been granted breakthrough therapy designation in the United States for acyclovir-resistant HSV in immunocompromised patients.
In one notable case, an immunocompromised patient with recurrent herpes simplex encephalitis that was not responding to acyclovir alone received pritelivir as an add-on therapy. Within days, the patient’s level of awareness began improving. After four weeks, the viral load in spinal fluid dropped below detectable levels. Testing confirmed that pritelivir reached the spinal fluid at concentrations about four times higher than needed to inhibit HSV-1 in the lab.23npj Antimicrobials and Resistance. Treatment of Herpes simplex encephalitis with the helicase-primase inhibitor pritelivir in an immunocompromised patient That is just a single case, but it hints at the potential for these drugs in situations where standard treatment fails.
Recent structural biology work has revealed exactly how pritelivir and amenamevir latch onto the helicase-primase complex and block its ability to unwind DNA, giving drug designers a detailed blueprint for improving existing compounds or engineering new ones.24PubMed Central. Structural basis of herpesvirus helicase-primase inhibition by pritelivir and amenamevir
Gene Editing as a Potential Cure
Antivirals suppress HSV-1 but cannot eliminate the latent virus sitting inside neurons. That is why researchers have turned to gene editing as a genuinely curative approach. The idea is to send molecular scissors into the nerve cells harboring dormant HSV-1 and cut the viral DNA apart, destroying the reservoir that gives rise to lifelong infection.
One team using engineered meganucleases (a type of gene-editing tool) delivered by viral vectors reported eliminating 90% or more of latent HSV-1 DNA in mouse models of oral infection and up to 97% in models of genital infection.25Nature Communications. Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo A separate group used CRISPR-Cas9 gene editing in lab-grown brain organoids and found that treated organoids had reactivation rates of only 10–20% compared with 50% in untreated controls, along with viral loads roughly a thousand-fold lower.26PubMed Central. Suppression of HSV-1 infection and viral reactivation by CRISPR-Cas9 gene editing in 2D and 3D culture models
These results are impressive in animal and lab models, but translating them to humans involves significant hurdles. The editing tools need to reach essentially all latently infected neurons, which are scattered across one or more ganglia. Off-target cuts in human DNA are a safety concern. And delivering gene-editing cargo to neurons deep in the body is technically difficult. Still, this line of research represents the closest anyone has come to an actual cure rather than lifelong suppression.
Why There Is Still No Vaccine
Despite more than 70 years of effort, no approved vaccine exists for HSV-1 or HSV-2, either for prevention or treatment.27PubMed Central. A review of HSV pathogenesis, vaccine development, and advanced applications The main obstacle is the virus’s ability to hide in neurons in a near-invisible latent state. During latency, HSV-1 expresses almost no proteins for the immune system to target. And the virus has evolved multiple strategies to evade immune detection even during active infection, including interfering with the way infected cells present viral fragments to immune cells.
Several vaccine approaches are in preclinical or early clinical trials, including live attenuated viruses (weakened versions of HSV), protein subunit vaccines (pieces of viral protein combined with immune-stimulating additives), and nucleic acid vaccines (mRNA or DNA that instruct the body to make viral proteins temporarily).28PubMed Central. Developments in Vaccination for Herpes Simplex Virus Some candidates aim to prevent infection entirely; others aim to reduce recurrence frequency or shedding in people already infected. No candidate has yet demonstrated strong enough efficacy in large human trials to move toward approval.
HSV-1 and Alzheimer’s Disease
A growing body of research has drawn a connection between HSV-1 and Alzheimer’s disease. The virus has been found in brain regions affected by Alzheimer’s, and emerging evidence links it to chronic brain inflammation, buildup of amyloid-beta plaques and tau tangles, and damage to synapses, the connections between nerve cells.29PubMed Central. HSV-1 as a Potential Driver of Alzheimer’s Disease Lab and animal studies have shown that infecting brain cells with HSV-1 can trigger amyloid deposits and the abnormal phosphorylation of tau, two hallmarks of Alzheimer’s.30Scientific Reports. Association between herpes simplex virus infection and Alzheimer’s disease biomarkers: analysis within the MAPT trial
In transgenic mice engineered to develop Alzheimer’s-like pathology, HSV-1 infection of the brain accelerated amyloid buildup, increased inflammation-related immune cell activity, and worsened cognitive decline compared with uninfected mice. The mechanism appeared to involve activation of a specific inflammatory pathway (the NLRP3 inflammasome) that sits at the intersection of viral infection and amyloid accumulation.31PubMed Central. Herpes simplex virus 1 accelerates the progression of Alzheimer’s disease by modulating microglial phagocytosis and activating NLRP3 pathway
This does not mean HSV-1 “causes” Alzheimer’s in any straightforward sense. Most of the world’s population carries HSV-1, and most do not develop dementia. But the repeated cycles of reactivation and inflammation in the brain over a lifetime, combined with genetic susceptibility factors like the APOE4 gene variant, could plausibly contribute to neurodegenerative processes in some individuals. The hypothesis is testable: if HSV-1 contributes to Alzheimer’s risk, effective antiviral treatment or vaccination should reduce that risk. Some retrospective epidemiological studies have pointed in that direction, but the evidence is not yet strong enough to change clinical practice.
The Stigma Problem
Given that roughly two-thirds of people under 50 carry HSV-1, the level of stigma attached to herpes is strikingly disproportionate to its prevalence. Genital herpes stigma in particular can cause significant psychological distress, including anxiety, depression, feelings of shame, and reluctance to disclose infection status to sexual partners.32PubMed Central. Genital herpes stigma: Toward the Measurement and Validation of a highly prevalent yet hidden public health problem Research suggests a self-reinforcing cycle: stigma-related distress and poor coping may contribute to more frequent outbreaks, and those outbreaks in turn increase the psychological salience of the stigma.33PubMed. The psychological impact of genital herpes stigma
The stigma also has a public health cost. People who fear judgment are less likely to get tested, less likely to disclose, and less likely to seek treatment, all of which can contribute to further transmission. The widespread conflation of “herpes” with sexual irresponsibility ignores the reality that most people acquire HSV-1 in childhood through non-sexual contact, and that genital HSV-1 is increasingly common through entirely ordinary sexual behavior.
HSV-1 Repurposed Against Cancer
In an ironic twist, the same properties that make HSV-1 dangerous in the brain, its ability to infect cells, replicate vigorously, and trigger a strong immune response, have been harnessed for cancer treatment. Talimogene laherparepvec (T-VEC) is a genetically modified HSV-1 that was engineered to replicate selectively inside tumor cells rather than normal tissue. Key safety modifications include deletion of the viral genes responsible for nerve damage. The modified virus also carries a gene for an immune-stimulating protein that helps the body recognize and attack tumor cells even at sites distant from the injection.34PubMed Central. Talimogene laherparepvec: First in class oncolytic virotherapy
T-VEC became the first oncolytic virus therapy approved by the FDA, for use in advanced melanoma that cannot be surgically removed. It is injected directly into accessible tumors. While not a standalone cure for melanoma, it marked a conceptual milestone: a human pathogen redesigned from the ground up to fight a completely different disease.35PubMed Central. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
An Ancient Companion
HSV-1 has been with our species for a very long time. The virus’s genetic diversity mirrors human migration patterns, with distinct viral lineages clustering geographically in ways that track the movement of human populations out of Africa thousands of years ago.36PubMed Central. Evolutionary Origins of Human Herpes Simplex Viruses 1 and 2 Ancient DNA analysis has added a fascinating wrinkle. Researchers sequenced full HSV-1 genomes from European archaeological remains dating from the 3rd to 17th century CE and used those sequences to estimate when the current diversity of Eurasian HSV-1 lineages arose. The answer was surprisingly recent: roughly 5,000 years ago, coinciding with the late Neolithic and early Bronze Age. This suggests a large-scale replacement of earlier viral lineages, possibly driven by the massive population movements and mixing that defined that period of human history.37PubMed Central. Ancient herpes simplex 1 genomes reveal recent viral structure in Eurasia
The implication is that the HSV-1 strains circulating today in Europe and Asia are not the same lineages that infected the earliest modern humans in those regions. Waves of human migration carried new viral strains that outcompeted or replaced older ones, a pattern that mirrors what has been seen with other pathogens carried since prehistory. HSV-1 is, in effect, a passenger that has been rewriting its own passenger manifest every time humanity has reshuffled.